Abstract
Oridonin, an ent-kaurane diterpenoid mainly extracted from Chinese medical plant Rabdosia rubescens and some related species, has been reported its remarkable antitumor efficacy in various cancer cells. This review will be focused on the underlying molecular mechanisms for the treatments of oridonin in hematological malignancies, which include the regulation of oncoproteins (AML1-ETO, NPM1 mutants, PML-RARα, ABL kinase), accumulation of ROS, modulation of MAPKs and PI3K/Akt signaling pathways, and changes of abnormal expressions of MicroRNAs. And we get the conclusion that oridonin is a promising natural product with multiple targets against hematological malignancies.
Keywords: Oridonin, molecular mechanism, antitumor, hematological malignancies.
Current Pharmaceutical Biotechnology
Title:Oridonin, a Promising Antitumor Natural Product in the Chemotherapy of Hematological Malignancies
Volume: 15 Issue: 11
Author(s): Zichu Zhao and Yan Chen
Affiliation:
Keywords: Oridonin, molecular mechanism, antitumor, hematological malignancies.
Abstract: Oridonin, an ent-kaurane diterpenoid mainly extracted from Chinese medical plant Rabdosia rubescens and some related species, has been reported its remarkable antitumor efficacy in various cancer cells. This review will be focused on the underlying molecular mechanisms for the treatments of oridonin in hematological malignancies, which include the regulation of oncoproteins (AML1-ETO, NPM1 mutants, PML-RARα, ABL kinase), accumulation of ROS, modulation of MAPKs and PI3K/Akt signaling pathways, and changes of abnormal expressions of MicroRNAs. And we get the conclusion that oridonin is a promising natural product with multiple targets against hematological malignancies.
Export Options
About this article
Cite this article as:
Zhao Zichu and Chen Yan, Oridonin, a Promising Antitumor Natural Product in the Chemotherapy of Hematological Malignancies, Current Pharmaceutical Biotechnology 2014; 15 (11) . https://dx.doi.org/10.2174/1389201015666141111115608
DOI https://dx.doi.org/10.2174/1389201015666141111115608 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Stem Cell Research & Therapy Lung Cancer May Increase Serum Procalcitonin Level
Infectious Disorders - Drug Targets Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma
Current Radiopharmaceuticals Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Possible Mechanisms of Lymphoma Development in Sjogren’s Syndrome
Current Immunology Reviews (Discontinued) Cdc25A Protein Phosphatase: A Therapeutic Target for Liver Cancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stromal Cells; Role in Tissue Repair, Drug Discovery and Immune Modulation
Current Drug Delivery Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?
CNS & Neurological Disorders - Drug Targets Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets JAK2 as a Molecular Marker in Myeloproliferative Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety Synthesis, Docking and Anti-Tumor Activity of β-L-1,3-Thiazolidine Pyrimidine Nucleoside Analogues
Medicinal Chemistry Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review
Anti-Cancer Agents in Medicinal Chemistry Development of Extracellular Signal-Regulated Kinase Inhibitors
Current Topics in Medicinal Chemistry Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets